CHANGES IN LIPID AND CARBOHYDRATE METABOLISM IN PATIENTS WITH GOUT AND NON-ALCOHOLIC STEATOHEPATITIS
DOI:
https://doi.org/10.11603/1811-2471.2020.v.i1.11067Keywords:
gout, non-alcoholic steatohepatitis, lipid metabolism, carbohydrate metabolismAbstract
Pathology of the joint apparatus is one of the frequent and common diseases in the population. Most often, among the so-called saline arthropathies, gout is detected, the clinical course of which is significantly affected by comorbid pathology. The combination of gout and non-alcoholic steatohepatitis is a pressing issue today, as both diseases are multisystemic with metabolic and cardiovascular disorders.
The aim of the study – to detect changes in lipid and carbohydrate metabolism and to evaluate the clinical manifestations of the disease in patients with gout in combination with nonalcoholic steatohepatitis.
Material and Methods. The study involved 123 patients with gout during the exacerbation period, including 118 (95.9 %) men and 5 (4.1 %) women. Patients underwent general clinical examination (complaint collection, medical history, measurements of height and body weight) and biochemical tests (determined liver functional tests, lipid spectrum, carbohydrate metabolism, as well as serum levels of uric acid (UA) as a marker of disruption of purine metabolism).
All surveyed were divided into two groups. Group I included 65 patients with gout without liver damage, group II included 58 people with concomitant NASH. The comparison group consisted of 30 practically healthy persons.
It is established that the development of NASH in patients with gout is associated with major disorders of the functional state of the liver (increase in UA content, activity of ALT, AST, glycemia, total bilirubin, decrease in the level of total protein), accompanied by significant dys- and hyperlipidemia.
Conclusion. The presence of NASH, as a concomitant disease in patients with gout, impairs their overall condition and quality of life. Deeper blood lipid abnormalities were established with the combined course of gout and NASH, which degrade the course of the underlying disease and increases the risk of cardio-vascular events.
References
Herasymenko, S.I., Poluliakh, M.V., Duda, M.S. & Pshenychnyi, T.Ie. (2013). Suchasni aspekty konservatyvnoho likuvannia hostroho podahrychnoho artrytu [Current aspects of conservative treatment of acute gouty arthritis]. Litopys travmatolohii ta ortopedii – Chronicle of Traumatology and Orthopedics, (1-2), 204-207 [in Ukrainian].
Bardin, T., & Richette, P. (2017). Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC medicine, 15 (1), 123. doi:10.1186/s12916-017-0890-9. DOI: https://doi.org/10.1186/s12916-017-0890-9
Kambachokova, Z.A., & Aramisova, R.M. (2018). Trudnosti vedeniya patsiyentov s podagroy na fone komorbidnykh sostoyaniy [Difficulties in managing patients with gout amid comorbid conditions]. Trudnyy patsiyent – Difficult Patient, 16 (6), 46-52 [in Russian].
Maltsev, D.V., Natrus, L.V., Kondratiuk, V.Ye., & Degtyarova, I.E. (2018). Immunological aspects of pathogenesis of gout in light of recent scientic discoveries as a key for development of informative biomarkers and innovative therapeutic strategies. Studia Biologica, 12 (3-4), 103-116. DOI: 10.30970/sbi.1203.572. DOI: https://doi.org/10.30970/sbi.1203.572
Svintsitskyi, A.S., Kozak, N.P., & Ostafiichuk, A.S. (2011). Osoblyvosti perebihu podahry na foni metabolichnoho syndromu [Features of the course of gout on the background of metabolic syndrome]. Ukr. revmatol. zh. – Ukrainian Rheumatology Journal, (4), 46 [in Ukrainian].
Skliarov, Ye.Ya., Aksentiichuk, Kh.B., & Kurliak, N.V. (2015). Monitorynh porushen funktsii pechinky u patsiientiv z nealkoholnoiu zhyrovoiu khvoroboiu pechinky na tli metabolichnoho syndromu [Monitoring of liver function disorders in patients with non-alcoholic fatty liver disease on the background of metabolic syndrome]. Hepatolohiia –Hepatology, (1), 34-41 [in Ukrainian].
Younossi, Z.M. (2019). Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology, 70 (3), 531-544. PMID:30414863 doi: 10.1016/ j.jhep.2018.10.033. DOI: https://doi.org/10.1016/j.jhep.2018.10.033
Ryu, S., Chang, Y., Kim, S.G., Cho, J., & Guallar, E. (2011). Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism, 60 (6), 860-866. DOI: https://doi.org/10.1016/j.metabol.2010.08.005
Shih, M.H., Lazo, M., Liu, S.H., Bonekamp, S., Hernaez, R., & Clark, J.M. (2015). Association between serum uric acid and nonalcoholic fatty liver disease in the US population. Journal of the Formosan Medical Association, 114 (4), 314-320.
Danchak, S.V. (2015). Dysmetabolichni porushennia u patsiientiv iz podahroiu v poiednanni z nealkoholnoiu zhyrovoiu khvoroboiu pechinky [Dysmetabolic disorders in patients with gout in combination with non-alcoholic fatty liver disease]. Visnyk naukovykh doslidzhen – Bulletin of Scientific Research, (3), 56-58 [in Ukrainian].
Yang, Y., Zhou, Y., Cheng, S., Sun, J. L., Yao, H., & Ma, L. (2016). Effect of uric acid on mitochondrial function and oxidative stress in hepatocytes. Genet. Mol. Res., 15 (2). DOI: https://doi.org/10.4238/gmr.15028644
Hrytsenko, M.V. (2018). Vplyv metabolichnoho syndromu na stan funktsii nyrok u patsiientiv, shcho tryvalo khvoriiut na podahru [Influence of metabolic syndrome on kidney function in patients with chronic gout]. Zhurnal klinichnykh ta eksperymentalnykh medychnykh doslidzhen – Journal of Clinical and Experimental Medical Research, 6 (4), 447-452 [in Ukrainian].
Afzali, A., Weiss, N.S., Boyko, E.J., & Ioannou, G.N. (2010). Association between serum uric acid level and chronic liver disease in the United States. Hepatology, 52 (2), 578-589. DOI: https://doi.org/10.1002/hep.23717
Shih, M.H., Lazo, M., Liu, S.H., Bonekamp, S., Hernaez, R., & Clark, J.M. (2015). Association between serum uric acid and nonalcoholic fatty liver disease in the US population. Journal of the Formosan Medical Association, 114 (4), 314-320. DOI: https://doi.org/10.1016/j.jfma.2012.11.014
